Role of prostaglandins and leukotrienes in complement-initiated lung vascular injury.
D000818:Animals; D002396:Catechols / Q000494:pharmacology*; D003167:Complement Activation; D011464:Epoprostenol / Q000097:blood*; D006976:Hypertension, Pulmonary / Q000097:blood* / Q000139:chemically induced; D000860:Hypoxia / Q000139:chemically induced; D007962:Leukocytes / Q000187:drug effects*; D007975:Leukotriene B4 / Q000037:antagonists & inhibitors*; D009637:Masoprocol; D008469:Meclofenamic Acid / Q000494:pharmacology*; D010105:Oxygenases / Q000037:antagonists & inhibitors; D011453:Prostaglandins / Q000097:blood*; D011652:Pulmonary Circulation / Q000187:drug effects; D012756:Sheep; D015054:Zymosan; D062367:ortho-Aminobenzoates / Q000494:pharmacology*
D002396:Catechols; D011453:Prostaglandins; D062367:ortho-Aminobenzoates; D007975:Leukotriene B4; D008469:Meclofenamic Acid; D009637:Masoprocol; D015054:Zymosan; D011464:Epoprostenol; D010105:Oxygenases